Biotech Hangout · Health & Longevity · November 2026
A co-host worried that pharma may bypass small US biotechs by going straight to China and to AI-driven drug discovery. Gline answers that the only defense is to compete on quality. He also says he doubts AI will change things quickly.
…the biotech industry as where the drugs are being developed. And so, if the drugs are being developed by AI companies and in China, I think that's great for the biotech industry and bad for the companies that aren't developing the drugs. So, that's just like a slightly point of view that I have.
…go and acquire the U.S. biotechs when so it's more of the pharma play, not what's happening in China in terms of drug discovery or licensing for biotech, which they potentially are trying to restrict. The issue is, is pharma going to not need the biotech as much if they can go direct to the source?
Yeah, I guess I just think if biotech companies or AI companies can, sorry, if Chinese companies or AI companies can develop drugs, better drugs, cheaper and faster than conventional U.S. biotech companies, then I think conventional U.S. biotech companies, Reivan included, need to reinvent ourselves to take advantage of drug development pathways in China and AI. I have said other places I'm a little bit skeptical about AI revolutionizing things quickly, but I do think we owe it to all of ourselves. The reason that global pharma companies buy U.S. biotech companies is because they have the best drugs. If we want to keep getting bought, we got to keep developing the best drugs. That to me is like an oversimple characterization, but I just feel like being afraid of new people coming in and developing drugs faster and better. Like that's just that to me shouldn't be the tone of the industry. I guess this to me is a little bit what Bruce and Peter both, I think, have advocated for.
Yeah. And by the way, I'm more in their camp, but what I'm saying is that we're seeing more earlier deals in pharma. They're not afraid to go early, pull it inside. It's not a China AI versus biotech. It's a pharma versus U.S. biotech. And so that's what I'm interested to watch. I am more in the…
pharma historically has. Anyway, we'll see how pharma does with early stage drug development as time goes on. Isomorphic raised, I think, $5 billion at a $50 billion valuation. And, you know, I think isomorphic has been around a little bit, but this is obviously just an incredibly eye-popping…
I think that's a very fair point, Matt. There's a lot of other stuff that